发明名称 14.ALPHA.,17.ALPHA.-C2-BRIDGED 19-NOR-PROGESTERONE DERIVATIVES
摘要 The invention concerns 14,17-C2-bridged steroids of general formula (I), wherein: R3 represents an oxygen atom, the hydroxy amino group or two hydrogen atoms; R6 represents either a hydrogen, fluorine, chlorine or bromine atom or a C1-C4 alkyl group at the .alpha. or .beta. position, R6' and R7 then representing hydrogen atoms; or alternatively, R6 represents a hydrogen, fluorine, chlorine or bromine atom or a C1-C4 alkyl group, R6' and R7 then representing a common additional bond; R7 represents a C1-C4 alkyl group at the .alpha. or .beta. position, R6 and R6' then representing hydrogen atoms; or alternatively R6 and R7 together represent a methylene group at the .alpha. or .beta. position and R6' represents a hydrogen atom; or R6 and R6' together represent an ethylene or methylene group and R7 represents a hydrogen atom; R9 and R10 each represent a hydrogen atom or a common bond; R11 and R12 each represent a hydrogen atom or a common bond; R13 represents a methyl or ethyl group; R15 represents a hydrogen atom or a C1-C3 alkyl group; R16 and R16' independently of one another represent a hydrogen atom, a C1-C3 alkyl group, or a C2-C4 alkenyl group, or together represent a C1-C3 alkylidene group; R15 and R16 represent a common bond and R16' represents a hydrogen atom or a C1-C3 alkyl group, or alternatively R15 and R16 together represent a ring of the partial formula (i) shown, in which n = 1 and 2 and X represents a methylene group or an oxygen atom; and R16' represents a hydrogen atom; R171 represents a hydrogen atom or a C1-C3 alkyl group; R172 represents a hydrogen atom, a C1C3 alkyl group or a C2-C4 alkenyl group; R171' and R172' each represent a hydrogen atom or a common bond; R21 represents a hydrogen atom or a C1-C3 alkyl group; and R21' represents a hydrogen atom, C1-C3 alkyl group or hydroxy group. The claimed compounds do not include 14,17-ethano-19-norpregn-4-en-3,20-dione. The novel compounds, unlike the one disclaimed, show a high level of gestagenic activity even after peroral administration and are suitable for use in the production of medicaments.
申请公布号 CA2208605(A1) 申请公布日期 1996.07.04
申请号 CA19952208605 申请日期 1995.12.23
申请人 SCHERING AKTIENGESELLSCHAFT 发明人 MUHN, HANS-PETER;SCH LLKOPF, KLAUS;FRITZEMEIER, KARL-HEINRICH;KUHNKE, JOACHIM;SCHWEDE, WOLFGANG;KRATTENMACHER, ROLF;HALFBRODT, WOLFGANG
分类号 A61K31/56;A61K31/58;A61P43/00;C07J53/00;C07J71/00;(IPC1-7):C07J53/00;C07J21/00 主分类号 A61K31/56
代理机构 代理人
主权项
地址